Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 10, 2004, Pages 1700-1708

  Aledort, Louis M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Factor VII; Factor VIII; Postmarketing; Product surveillance; Thrombosis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BACTEREMIA; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HEART INFARCTION; HEMARTHROSIS; HEMOPHILIA; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFORMATION RETRIEVAL; LUNG EMBOLISM; MEDLINE; MESENTERIC VEIN THROMBOSIS; OCCLUSIVE CEREBROVASCULAR DISEASE; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; CHILD; DATA COLLECTION; FACTOR VII; HUMANS; INCIDENCE; INTRACRANIAL THROMBOSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 13244262642     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00944.x     Document Type: Article

References (66)

1. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor bypassing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
2. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients: FEIBA Study Group. Transfusion 1990; 30: 626-30.
3. Aledort L. Inhibitors in hemophilia patients. current status and management. Am J Hematol 1994; 47: 208-17.
4. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors: French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
5. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002; 88: 60-5.
6. Dejgaard A. Update on Novo Nordisk's clinical trial programme on NovoSeven®. Blood Coagul Fibrinolysis 2003; 14 (Suppl. 1): S39-41.
7. Arkin S, Blei F, Fetten J, Foulke R, Gilchrist GS, Heisel MA, Key N, Kisker CT, Kitchen C, Shafer FE, Shah PC, Strickland D. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255-9.
8. Negrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000; 26: 407-12.
9. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
10. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41 (Suppl. 1): 101-8.
11. Aledort LM. Recombinant factor VIIa is a pan-hemostatic agent? Thromb Haemost 2000; 83: 637-8.
12. Aledort LM. rFVIIa - its thromboenicity. Thromb Haemost 2000; 84: 522-3.
13. Aledort LM. Adverse reactions related to rVIIa? Am J Hematol 2001; 67: 213.
14. Aledort LM. Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient. are they appropriate and safe? J Thorac Cardiovasc Surg 2003; 126: 2112-3.
15. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J General Intern Med 2003; 18: 57-60.
16. Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel - a need for new approaches to drug safety. N Engl J Med 2000; 342: 1824-6.
17. Kessler DA, Introducing MED. Watch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-8.
18. Cicero TJ, Adams EH, Geller A, Inciardi JA, Munoz A, Schnoll SH, Senay EC, Woody GE. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999; 57: 7-22.
19. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Safety 2002; 25: 537-44.
20. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-11.
21. Labenz J, Petersen KU, Rösch W, Koelz HR. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003; 17: 1015-9.
22. Koller EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's MedWatch surveillance system and published reports. Pharmacotherapy 2003; 23: 1123-30.
23. Ludlam CA. The evidence behind inhibitor treatment with recombinant factor VIIa. Pathophysiol Haemost Thromb 2002; 32 (Suppl. 1): 13-8.
24. Wysocki B Jr. 'Wonder drug' stops bleeding, but cost is high. Wall Street J 17 March 2004: B1-B2.
25. d'Oiron R, Ménart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Négrier C. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-7.
26. Jansen M, Schmaldienst S, Banyai S, Quehenberger P, Pabinger I, Derfler K, Hörl WH, Knöbl P. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-7.
27. Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-6.
28. Grünewald M, Beneke H, Güthner C, Germowitz A, Brommer A, Griesshammer M. Acquired haemophilia: experiences with a standardized approach. Haemophilia 2001; 7: 164-9.
29. Guillet B, Pinganaud C, Proulle V, Dreyfus M, Lambert T. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII. Thromb Haemost 2002; 88: 698-9.
30. van der Planken MG, Schroyens W, Vertessen F, Michiels JJ, Berneman ZN. Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion. Blood Coagul Fibrinolysis 2002; 13: 367-70.
31. Ng H, Loh YSM, Ho LP, Tien SL. Thrombotic events associated with the used of recombinant VIIa in a single institution: a role for caution. J Thromb Haemost 2003; 1 (Suppl. 1): P1123.
32. Hough RE, Preston FE, Hamptom KK, West JN, Channer KS, Markis M. rVIIa in patients with prothrombin complex concentrate (PCC) related myocardial infarction (MI). Haemophilia 2000; 6: 302.
33. Hough RE, Hampton KK, Preston FE, Changer KS, West J, Makris M. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors. Br J Haematol 2000; 111: 974-9.
34. Koksch M, Siegemund A, Siegemund T, Langpeter D, Engelmann L. Myocardial infarction during FEIBA treatment of acquired FVIII inhibitor-induced bleeding. Haemophilia 2000; 6: 294-5.
35. Tjønnfjord GE, Brinch L, Brosstad F, Evensen SA. The Norwegian experience with FEIBA® as first choice in surgery for patients with inhibitors 1996-2001. Haemophilia 2002; 8: 545-6.
36. Carcao MD, Connolly BL, Chait P, Stain AM, Acebes M, Massicotte P, Blanchette VS. Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia 2003; 9: 578-83.
37. Tjønnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174-8.
38. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124: 852-4.
39. Rosenfeld SB, Watkinson KK, Thompson BH, Macfarlane DE, Lentz SR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002; 87: 925-6.
40. DellaCroce FJ, Kountakis S, Aguilar EF 3rd. Manifestations of factor VIII inhibitor in the head and neck. Arch Otolaryngol Head Neck Surg 1999; 125: 1258-61.
41. Liebman HA, Chediak J, Fink KI, Galvez AG, Shah PC, Sham RL. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63: 109-13.
42. Bryant PC, Carr ME Jr, Martin EJ, Sutton JF. High dose recombinant activated factor VII in a pediatric patient with factor VIII deficiency and high titer inhibitor. Blood 2003; 102: 4128.
43. Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor. Thromb Res 1989; 56 603-9.
44. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Buller HR. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103: 2555-9.
45. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol 1998; 45: 427-31.
46. Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate®): a prospective pharmacovigilance study. Haemophilia 2004; 10: 1-8.
47. Kimmel SE, Sekeres MA, Berlin JA, Goldberg LR, Strom BL. Adverse events after protanime administration in patients undergoing cardiopulmonary bypass: risks and predictors of under-reporting. J Clin Epidemiol 1998; 51: 1-10.
48. Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358: 1872-3.
49. Rawlins MD. Spontaneous reporting of adverse drug reactions. I. the data. Br J Clin Pharmacol 1988; 26: 1-5.
50. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Safety 2001; 24: 233-7.
51. Pierfitte C, Begaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 1999; 47: 329-31.
52. Fletcher AP. An appraisal of spontaneous adverse event monitoring. Adverse Drug React Toxicol Rev 1992; 11: 213-27.
53. Ehrlich H, Henzl M, Gomperts E. Thrombotic events are very rare after infusion of factor VIII inhibitors bypass activity (FEIBA). Blood 2000; 96: 82b.
54. Ehrlich H, Henzl M, Gomperts E. Thrombotic events are very rare after infusion of factor VIII inhibitor bypass activity (FEIBA). Thromb Haemost 2001; 86 (Suppl. ): 2544.
55. Lusher JM. Inhibitors in young boys with haemophilia. Baillieres Best Pract Res Clin Haematol 2000; 13: 457 68.
56. Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001; 8: 312-8.
57. Laffan M, O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy D, Smith OP. Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagul Fibrinolysis 2003; 14 (Suppl. 1): S35-8.
58. Midathada MV, Mehta P, Waner M, Fink LM. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004; 121 124-37.
59. Jander S, Sitzer M, Wendt A, Schroeter M, Buchkremer M, Siebler M, Müller W, Sandmann W, Stoll G. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 2001; 32: 850-4.
60. Todoroki H, Nakamura S, Higure A, Okamoto K, Takeda S, Nagata N, Itoh H, Ohsato K. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127: 209-16.
61. Abshire T, Kenet G. Recombinant factor VIIa. review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2 899-909.
62. Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol 1994; 47: 36-40.
63. Stieltjes N, Ounnoughhene N, Vassilieff D, Sultan Y. Failure of recombinant factor VIIa to control surgical bleeding in a severe hemophilia A patient with an inhibitor and possible DIC. Thromb Haemost 1997; 77 (Suppl.): PS-202.
64. Juvonen E, Kolho E, Anttila VJ, Lommi J, Nissinen M, Rasi V. Acute myocardial infarction complicating therapy with F VIII followed by APCC and rFVIIa in a 26-year-old man with haemophilia A and F VIII inhibitor. Haemophilia 1998; 4: 338.
65. Schulman S. Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia 1998; 4: 564-7.
66. Chaganti S, Wilson J, Britnell T, Wilde JT. Frontal lobe ischaemia in association with FEIBA therapy. Haemophilia 2002; 8 539.